Global Toxoplasmosis Treatment Drugs Market: Drivers

The global Toxoplasmosis Treatment Drugs Market is expected to witness significant growth during the forecast period as pharmaceutical companies are focusing on research and development of treatments for toxoplasmosis. For instance, in 2018, Vyera Pharmaceuticals LLC received the U.S. Food Drug and Administration (FDA) clearance to initiate Phase 1 study of the VYR-006, which is a potent dihydrofolate reductase (DHFR) inhibitor used for treatment of toxoplasmosis.

Toxoplasmosis is an infection caused by parasite toxoplasma gondi. Moreover, toxoplasma gondi parasites are present in contaminated food. Moreover, accidental swallowing of the parasite spread through various sources like contact of cat feces, any infected blood, through infected organ transplantation, and drinking contaminated water, which can also cause toxoplasmosis infection. Toxoplasmosis infections can transmit toxoplasma gondi from the mother to child during pregnancy. Most patients suffering from toxoplasmosis infection recover without treatment but in case of serious toxoplasmosis infection, combination of pyrimethamine and sulfadiazine are usually prescribed by doctors. Additionally, the pyrimethazine drug also reduces the level of folic acid in patients, therefore, Vitamin B supplement is recommended along with pyrimethamine drug.

Patients suffering from AIDS or HIV and toxoplasmosis may have to continue medication such as pyrimethamine for rest of their lives. Spiramycin is usually prescribed by the doctor in first and early second trimester stage of pregnancy to reduce the transmission of infection to the fetus. During the last and third trimester stage, a combination of pyrimethamine/sulfadiazine and leucovorin is prescribed for pregnancy cases.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/toxoplasmosis-treatment-drugs-market-4166

Moreover, the growing prevalence of HIV across the globe is increasing risk of toxoplasma gonad infection due to less immune response in HIV infected patients. For instance, according to the World Health Organization (WHO), by the end of 2018, around 37.9 million people across the globe had HIV, therefore it is expected to increase prevalence of toxoplasmosis infection among the global population.

Global Toxoplasmosis Treatment Drugs: COVID-19 Impact Analysis

The COVID-19 pandemic has impacted growth of several markets across the globe and it is also expected to hamper the growth of the global toxoplasmosis treatment drugs market during the forecast period. Moreover, safety precautions suggested by the World Health Organization to reduce the spread of COVID-19 and implementation of nationwide lockdowns have affected the supply chain of toxoplasmosis treatment drugs due to higher shipping prices because of reduced excipient supply containers.

Global Toxoplasmosis Treatment Drugs Market: Restraints

The use of pyrimethanine and sulfadiazine drugs are characterized by side effects in pregnant women such as injury to the fetus and bone marrow suppression. Moreover, according to U.S. Food Drug and Administration’s February 2020 report, the most common side effect of pyrimethamine is hypersensitivity, which leads to severe diseases such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Furthermore, low dosage of promethazine can also cause hematologic effects in patients. These factors are expected to restrain growth of the global toxoplasmosis treatment drugs market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4166

Global Toxoplasmosis Treatment Drugs Market: Regional Analysis

On the basis of region, the global toxoplasmosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In 2020, North America is expected to account the largest market share in the global toxoplasmosis treatment drugs market owing to factors such as the increasing prevalence of toxoplasmosis infection. According to the Centers for Disease Control and Prevention’s September 2018 report, in the U.S, around 11% of the population in the age group of 6 or older suffered from toxoplasma.

Furthermore, pharmaceutical companies are focusing on research and development of effective treatments for toxoplasmosis to strengthen their market share in the global toxoplasmosis treatment drugs market. For instance, in February 2020, Cerovene Inc. obtained approval for generic Daraprim (pyrimethamine) tablet for treatment of toxoplasmosis from the U.S. FDA. The drug is used with combination of sulfonamide for treatment of toxoplasmosis bacterial infection.

Europe is expected to witness significant growth in the global toxoplasmosis treatment drugs market due to the rising prevalence of HIV in Europe. For instance, according to the World Health Organization’s 2018 report, over 2 million people in Europe were affected by HIV.

Global Toxoplasmosis Treatment Drugs Market: Key Players

Key players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4166

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737